Takeda touts a landmark head-to-head PhIIIb win over Humira; Allergan's oral CGRP is now under FDA review
→ Takeda $TAK says their drug Entyvio has beat out AbbVie’s $ABBV Humira in a head-to-head study for ulcerative colitis. Researchers pointed to a 31.3% remission rate for their drug, compared to 22.5% for the Humira arm at week 52. The company added that this is the first head-to-head study of 2 biologics for UC.
→ An oral CGRP for migraine is now under FDA review. The drug — ubrogepant — from Allergan $AGN is set to help the millions of migraine sufferers who now have a menu of injectable preventative CGRP treatments at their disposal, but are looking for that as-needed medicine to deal with the odd migraine that sneaks up. The FDA is expected to make its decision on the drug — that Allergan got from Merck $MRK in 2015 — by the fourth quarter. If approved, ubrogepant could potentially be used in combination with its anti-CGRP injectable rivals and/or Allergan’s own versatile Botox injection.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.